An Open-Label, Dose-escalation, Phase I/IIa Study to Determine the Maximum Tolerated Dose, Recommended Dose, Efficacy, Pharmacokinetics and Pharmacodynamics of the Dual VEGFR-FGFR Tyrosine Kinase Inhibitor, E-3810, Given Orally as Single Agent to Patients With Advanced Solid Tumours

Trial Profile

An Open-Label, Dose-escalation, Phase I/IIa Study to Determine the Maximum Tolerated Dose, Recommended Dose, Efficacy, Pharmacokinetics and Pharmacodynamics of the Dual VEGFR-FGFR Tyrosine Kinase Inhibitor, E-3810, Given Orally as Single Agent to Patients With Advanced Solid Tumours

Completed
Phase of Trial: Phase I/II

Latest Information Update: 19 May 2017

At a glance

  • Drugs Lucitanib (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors EOS S.p.A.; Servier
  • Most Recent Events

    • 12 May 2017 Status changed from active, no longer recruiting to completed.
    • 11 Mar 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Sep 2016, as reported by ClinicalTrials.gov.
    • 09 Sep 2015 Interim results in a subgroup of patients with thymic epithelial tumours (n=15) presented at the 16th World Conference on Lung Cancer.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top